Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 16,852 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Tract Disease Clear all
Withdrawn Not applicable Interventional

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

NCT00741767
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Sleep Disorders
Interventions
salmeterol-fluticasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Assessment of Acute Disease to Reduce Imaging Costs

NCT01059500
View directory record Official record
Conditions
Acute Coronary Syndrome, Pulmonary Embolism
Interventions
Webtool
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 99 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Jackson, Mississippi • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

NCT05882734
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
M1774, Cemiplimab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Santa Monica, California • Pittsburgh, Pennsylvania • Knoxville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Recruiting No phase listed Observational

Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD

NCT07186699
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Thoracic Cancer
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Recruiting Phase 2 Interventional

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

NCT07635563
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01931787
View directory record Official record
Conditions
Recurrent Small Cell Lung Cancer
Interventions
6,8-bis(benzylthio)octanoic acid
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

NCT03681093
View directory record Official record
Conditions
Nasal Polyps
Interventions
Fevipiprant 150 mg, Fevipiprant 450 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 14, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational

Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma

NCT01690793
View directory record Official record
Conditions
ASTHMA
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )

NCT05281692
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Enhanced Preservation Media (EPM-IX)
Diagnostic Test
Lead sponsor
Convergent Genomics, Inc.
Network
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 14, 2026, 1:19 PM EDT
Recruiting Not applicable Interventional

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

NCT07224464
View directory record Official record
Conditions
Metastatic Solid Tumors, Stage 4 Cancer
Interventions
The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
Device
Lead sponsor
New Phase Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational

Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations

NCT04341532
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

NCT01408732
View directory record Official record
Conditions
Epistaxis, Hereditary Hemorrhagic Telangiectasia
Interventions
Sclerotherapy, Standard Treatment
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 14, 2026, 1:19 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT06995898
View directory record Official record
Conditions
Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Biospecimen Collection, Device Usage, Electronic Health Record Review, Multi-Cancer Detection Test, Questionnaire Administration
Procedure · Device · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 75 Years
Enrollment
24,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
45
States / cities
Pleasanton, California • Cheyenne Wells, Colorado • Denver, Colorado + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

NCT00084487
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
becatecarin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational

The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure

NCT02275793
View directory record Official record
Conditions
Diastolic Heart Failure, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 14, 2026, 1:19 PM EDT
Terminated Phase 3 Interventional Results available

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

NCT04811092
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Placebo
Drug · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
28
States / cities
Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 2)

NCT03653611
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
On-site Practice Assessment, Clinical Staff Questionnaires, Patient Opinion Surveys, Modular online COPD Education, COPD in Primary Care/CAPTURE Introduction Focus Groups
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

AT1001 for the Treatment of Long COVID

NCT05747534
View directory record Official record
Conditions
Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19
Interventions
Larazotide Acetate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 50 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00107809
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
60
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational

A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function

NCT04038047
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 14, 2026, 1:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Simulated In-House Usability Study of Eclipse Continuous Positive Airway Pressure (CPAP) Device

NCT05570747
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Usability
Other
Lead sponsor
Bleep, LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Asheville, North Carolina • Huntersville, North Carolina • Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

NCT03207243
View directory record Official record
Conditions
Asthma
Interventions
GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Avelumab in First-line NSCLC (JAVELIN Lung 100)

NCT02576574
View directory record Official record
Conditions
First Line Non-Small Cell Lung Cancer
Interventions
Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
21
States / cities
Huntsville, Alabama • Surprise, Arizona • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 14, 2026, 1:19 PM EDT